1394820-98-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-fluoro-4-nitrophenoxy)quinolin-7-ol is used as a chemical intermediate for the synthesis of various organic compounds, particularly in the development of new pharmaceuticals. Its unique structure and properties may contribute to the discovery of novel drug candidates with potential therapeutic applications.
Used in Materials Science:
In the field of materials science, 4-(2-fluoro-4-nitrophenoxy)quinolin-7-ol may be utilized in the development of advanced materials with specific properties. Its unique structure could potentially be incorporated into the design of new materials with applications in various industries, such as electronics, coatings, or sensors.
Used in Biological Research:
4-(2-fluoro-4-nitrophenoxy)quinolin-7-ol may also be employed in biological research to investigate its potential pharmacological uses. Its unique structure and properties could provide insights into its biological activity, which may lead to the identification of new therapeutic targets or the development of novel drugs.
Note: The specific applications and reasons for using 4-(2-fluoro-4-nitrophenoxy)quinolin-7-ol in different industries are not provided in the materials. The uses listed above are based on the general potential of the compound in pharmaceuticals, materials science, and biological research, considering its unique structure and properties. Further research and investigation are needed to fully understand its potential applications and effects.

Upstream product

• 1484-26-0 3-(benzyloxy)aniline 
• 749922-34-7 7-(benzyloxy)quinolin-4-ol 
• 178984-56-0 7-(benzyloxy)-4-chloroquinoline 
• 909345-85-3 5-((3-(benzyloxy)phenylamino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 403-19-0 2-fluoro-4-nitrophenol 
• 1039046-51-9 4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline 
• 68500-37-8 4-chloro-7-methoxyquinoline 

Downstream Products

• 1394820-99-5 1-((4-(2-fluoro-4-nitrophenoxy)quinolin-7-yl)oxy)-2-methylpropan-2-ol 
• 1394820-91-7 N-(3-fluoro-4-((7-((1-hydroxy-2-methylpropan-2-yl)oxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394821-11-4 methyl 2-((4-(2-fluoro-4-nitrophenoxy)quinolin-7-yl)oxy)-2-methylpropanoate 
• 1394821-12-5 2-((4-(2-fluoro-4-nitrophenoxy)quinolin-7-yl)oxy)-2-methylpropan-1-ol 
• 1394821-13-6 2-((4-(4-amino-2-fluorophenoxy)quinolin-7-yl)oxy)-2-methylpropan-1-ol 
• 1394821-10-3 2-((4-(2-fluoro-4-nitrophenoxy)quinolin-7-yl)oxy)-2-methylpropanoic acid 
• 1394820-69-9 N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394821-00-1 1-((4-(4-amino-2-fluorophenoxy)quinolin-7-yl)oxy)-2-methylpropan-2-ol 
• 1394821-01-2 4-(4-amino-2-fluorophenoxy)quinolin-7-ol 

Relevant academic research and scientific papers

Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2

New N-substituted-3-phenyl-1,6-naphthyridinone derivatives are designed and synthesized, based on structural modification of our previously reported compound 3. Extensive enzyme-based SAR studies and PK evaluation led to the discovery of compound 4r, with

Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate

A series of 1,6-naphthyridinone-based MET kinase inhibitors bearing quinoline moiety in block A were designed and synthesized based on the structures of Cabozantinib and our reported compound IV. Extensive SAR and DMPK studies led to the identification of 20j, a potent and orally bioavailable MET kinase inhibitor with favorable kinase selectivity. More importantly, 20j exhibited statistically significant tumor growth inhibition (Tumor growth inhibition/TGI of 131%, 4/6 partial regression/PR) in the U-87 MG xeograft model, which is superior to that of Cabozantinib (TGI of 97%, 2/6 PR), and significantly better than that of compound IV (TGI of 15%, 0/6 PR) at the same dose (12.5 mg/kg). Combined with favorable in vitro potency, kinase selectivity, pharmacokinetic profile and in vivo efficacy, the promising antitumor drug candidate 20j has subsequently advanced into preclinical research.

Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors

The overexpression of AXL kinase has been described in many types of cancer. Due to its role in proliferation, survival, migration, and resistance, AXL represents a promising target in the treatment of the disease. In this study we present a novel compound family that successfully targets the AXL kinase. Through optimization and detailed SAR studies we developed low nanomolar inhibitors, and after further biological characterization we identified a potent AXL kinase inhibitor with favorable pharmacokinetic profile. The antitumor activity was determined in xenograft models, and the lead compounds reduced the tumor size by 40% with no observed toxicity as well as lung metastasis formation by 66% when compared to vehicle control.

SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.